THE RESPONSE TO ATYPICAL
ANTIPSYCHOTIC DRUGS IN CORRELATION
WITH THE CYP2D6 GENOTYPE: CLINICAL
IMPLICATIONS AND PERSPECTIVES
LAURA NUSSBAUM1, RALUCA GRĂDINARU 2, NICOLETA
ANDREESCU2*, VICTOR DUMITRAȘCU3, ANCA TUDOR 4, LIANA
SUCIU5, RADU ȘTEFĂNESCU2,6, MARIA PUIU2
1Pedopsychiatry Discipline, Department of Neurosciences, University of
Medicine and Pharmacy “Victor Babeș”, Timișoara
2Genetics Discipline, Microscopic Morphology Department, University of
Medicine and Pharmacy “Victor Babeș”, Timișoara
3Pharmacology Discipline, Department of Biochemistry and
Pharmacology, University of Medicine and Pharmacy “Victor Babeș”,
Timișoara
4Discipline of Informatics and Medical Biostatistics, Department of
Functional Sciences, University of Medicine and Pharmacy “Victor
Babeș”, Timișoara
5Clinical Pharmacology Discipline, Faculty of Pharmacology, University
of Medicine and Pharmacy “Victor Babeș”, Timișoara
6Titu Maiorescu University, School of Medicine, Bucharest
*corresponding author: nicollandreescu@yahoo.com
Download Full Article

Abstract:

Atypical antipsychotics are widely used and have been shown to be effective
against both positive and negative symptoms of schizophrenia. Through this study we
intended to bring to the forefront attention the implications of pharmacogenetics for
obtaining the optimum results after antipsychotic treatment in a very sensitive category of
patients: children and adolescents. This study was performed between 2009 and 2013 and
includes children and adolescents with a diagnosis of schizophrenia or bipolar disorder. 81
patients, aged between 9 and 20 years were included in this study (median age was
15.74±4). The efficacy of the therapy was evaluated through the mean change in the
PANSS total scores from baseline- T0, through every timepoint - T1=after 3 months,
T2=after 6 months, T3=after 12 months, till endpoint - T4=after 18 months. Genotypes
were determined by measuring allele-specific fluorescence using the software for allelic
discrimination. Our results, showing statistically significant differences of the clinical score
between the groups classified based on the genotype, sustain the use of the
pharmacogenetic screening in clinical practice for the personalization of the therapy.

Top